WuXi Biologics (Cayman)

WuXi Biologics reported strong revenue and profit growth in the first half: revenue of 11.8 billion RMB (+18.4% year-on-year, +23.4% constant-currency) and adjusted net income of 3.9 billion RMB (+38.6%). Adjusted gross margin expanded to 48.4%, and EPS rose to $0.81 (+37.3%). Management raised the constant-currency revenue forecast for 2026 to 20–23% and expects a CAGR of at least 20% over three years, but sees risks from exchange rates, high capex plans (2026: 7.1 billion RMB; 2027: approx. $8 billion) and operational complexity from globalization. The company highlights growth drivers in complex modalities, biosimilars and AI-driven services, while investors weigh capex and currency pressure against strong operational momentum. » Más en de.investing.com

HanchorBio and WuXi Biologics signed a strategic collaboration in which WuXi will provide integrated development and GMP manufacturing services for HanchorBio's bi- and multifunctional fusion proteins. The goal is to accelerate clinical translation and increase production efficiency for HanchorBio's immunotherapy pipeline in oncology and autoimmune diseases. HanchorBio's stock is trading at $10.56 and is rated undervalued by InvestingPro. » Más en de.investing.com